Drug metabolism-associated genes have been clarified to play a vital role in the process of cancer cell growth and migration. Nevertheless, the correlation between drug metabolism-associated genes and gastric cancer (GC) has not been fully explored and clarified. This paper has focused on the role of aldehyde dehydrogenase 6 family member A1 (ALDH6A1), a drug metabolism-associated gene, in the immune regulation and prognosis of GC patients. Using several bioinformatics platforms and immunohistochemistry (IHC) assay, we found that ALDH6A1 expression was significantly down-regulated in GC tissues. Moreover, higher expression of ALDH6A1 was related to the better prognosis of GC patients. ALDH6A1 was also found to be involved in the regulation of several immune-associated signatures, including immunoinhibitors. In conclusion, the above results have concluded that aberrant expression of ALDH6A1 might be served as the promising predictor for prognosis and clinical immunotherapy response in GC patients.

中文翻译：

---

下调的药物代谢相关 ALDH6A1 可预测胃癌的预后和治疗性免疫反应

药物代谢相关基因已被阐明在癌细胞的生长和迁移过程中起着至关重要的作用。然而，药物代谢相关基因与胃癌（GC）之间的相关性尚未得到充分探索和阐明。本文重点研究了药物代谢相关基因醛脱氢酶 6 家族成员 A1 (ALDH6A1) 在胃癌患者免疫调节和预后中的作用。使用多个生物信息学平台和免疫组织化学 (IHC) 测定，我们发现 ALDH6A1 表达在 GC 组织中显着下调。此外，ALDH6A1 的高表达与胃癌患者的预后较好有关。还发现 ALDH6A1 参与了几种免疫相关特征的调节，包括免疫抑制剂。综上所述，